Integra LifeSciences (NASDAQ:IART) Trading Down 4.1% - Time to Sell?

Key Points

• Integra LifeSciences' stock price decreased by 4.1%, trading at $14.53, with a significant drop in trading volume.
• Analysts have lowered their price targets for the stock, with a notable cut from Wells Fargo from $25.00 to $13.00, reflecting overall cautious sentiment.
• Despite reporting earnings of $0.45 EPS for the last quarter, Integra's revenue declined by 0.6% year-over-year and the company has set FY 2025 guidance lower at 2.190-2.290 EPS.

Integra LifeSciences Holdings Corporation (NASDAQ:IART - Get Free Report)'s share price dropped 4.1% during mid-day trading on Wednesday . The stock traded as low as $14.58 and last traded at $14.53. Approximately 128,668 shares traded hands during mid-day trading, a decline of 88% from the average daily volume of 1,038,056 shares. The stock had previously closed at $15.16.

Integra LifeSciences Stock Performance

The firm has a fifty day moving average of $13.39 and a 200-day moving average of $15.69. The firm has a market cap of $1.22 billion, a P/E ratio of -2.40, a PEG ratio of 0.90 and a beta of 1.20. The company has a quick ratio of 0.73, a current ratio of 1.23 and a debt-to-equity ratio of 1.18.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.02. The business had revenue of $415.61 million for the quarter, compared to analysts' expectations of $395.06 million. Integra LifeSciences had a positive return on equity of 12.15% and a negative net margin of 30.87%.The firm's quarterly revenue was down .6% compared to the same quarter last year. During the same quarter last year, the business earned $0.63 earnings per share. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. Research analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Integra LifeSciences

Several hedge funds have recently added to or reduced their stakes in the company. Rubric Capital Management LP boosted its holdings in Integra LifeSciences by 58.4% in the second quarter. Rubric Capital Management LP now owns 7,353,934 shares of the life sciences company's stock valued at $90,233,000 after acquiring an additional 2,710,262 shares during the last quarter. Wellington Management Group LLP lifted its stake in Integra LifeSciences by 10.4% in the first quarter. Wellington Management Group LLP now owns 2,766,125 shares of the life sciences company's stock valued at $60,827,000 after buying an additional 259,987 shares during the period. Alliancebernstein L.P. lifted its stake in Integra LifeSciences by 5.0% in the first quarter. Alliancebernstein L.P. now owns 2,706,434 shares of the life sciences company's stock valued at $59,514,000 after buying an additional 128,041 shares during the period. Paradigm Capital Management Inc. NY lifted its stake in Integra LifeSciences by 57.5% in the second quarter. Paradigm Capital Management Inc. NY now owns 2,181,500 shares of the life sciences company's stock valued at $26,767,000 after buying an additional 796,300 shares during the period. Finally, Assenagon Asset Management S.A. lifted its stake in Integra LifeSciences by 2,418.7% in the first quarter. Assenagon Asset Management S.A. now owns 1,799,944 shares of the life sciences company's stock valued at $39,581,000 after buying an additional 1,728,480 shares during the period. Institutional investors own 84.78% of the company's stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.